Home>Topics>Companies>Cephalon

Cephalon CEPH

  1. All
  2. Commentary
  3. Headlines
    1. UPDATE 2-Teva to pay $512 mln to settle claims of delayed generic Provigil

      Headlines

      Mon, 20 Apr 2015

      April 20 (Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc , which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil.

    2. CORRECTED-UPDATE 1-Teva to pay $512 mln to settle claims of delayed generic Provigil

      Headlines

      Mon, 20 Apr 2015

      Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc , which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil

    3. UPDATE 1-Teva to pay $512 mln to settle claims of delayed generic Provigil

      Headlines

      Mon, 20 Apr 2015

      Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc , which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil

    4. Teva to pay $512 mln to settle claims of delayed generic Provigil

      Headlines

      Mon, 20 Apr 2015

      Reuters) - Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc , which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil

    5. Compelling Financial Benefit in Valeant's Latest Buy

      Headlines

      Fri, 27 Feb 2015

      record of success to be encouraging. He has demonstrated a willingness and ability to walk away from a target (Allergan, Cephalon , and so on) and avoids bidding wars whenever possible. He lacks a scientific background or experience in research and

    6. Why Retirement Funds Fall Short

      Headlines

      Tue, 2 Apr 2013

      Cephalon CEPH announced Monday that Gabitril did not ..... United States for partial seizures, but Cephalon had been working toward expanding the ..... back of regulatory delays for Sparlon, Cephalon 's drug for attention-deficit hyperactivity

    7. Teva Reports Disappointing News for Nuvigil Study in Bipolar Disorder

      Commentary

      Wed, 23 Jan 2013

      offset upcoming branded and generic competition for Copaxone. These events also raise our concern over the wisdom of the Cephalon acquisition. For now, however, we remain optimistic that Teva will succeed with the higher value products in its pipeline

    8. Teva Highlights Plan to Overcome Copaxone and Generic Industry Headwinds

      Commentary

      Wed, 12 Dec 2012

      conditions and pain) and respiratory products. This isn't particularly surprising, since these are the areas where Cephalon 's and Teva's capabilities in research and marketing had the most overlap, in our view. In light of Copaxone's

    9. Finding Good Pharma Stocks

      Headlines

      Thu, 10 May 2012

      offset the expiration, Teva bought two companies in 2011: Taiyo, the third largest generics company in Japan, and Cephalon , a global biotech company. These acquisitions will add to Teva’s earnings this year. In addition, Teva entered into a marketing

    10. Teva's Revenue Growth Falls Short on European Pricing Pressure

      Commentary

      Wed, 9 May 2012

      markets posted 30% growth. Boosted by the Cephalon acquisition, growth of 54% in Teva ..... into our forecast. The integration of Cephalon appears on track, and Teva's operating ..... realize synergies from the integration of Cephalon .

    « Prev12345Next »
    Content Partners